Cargando…
Early-stage non-alcoholic fatty liver disease in relation to atherosclerosis and inflammation
BACKGROUND AND AIMS: Non-alcoholic fatty liver disease (NAFLD) is a multisystem disease closely linked to cardiovascular disease (CVD). This study aims to investigate the connection between early-stage NAFLD and atherosclerosis, as well as the correlation between liver fibrosis and coronary heart di...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681951/ https://www.ncbi.nlm.nih.gov/pubmed/37952443 http://dx.doi.org/10.1016/j.clinsp.2023.100301 |
_version_ | 1785150872431362048 |
---|---|
author | Tan, Si-hua Zhou, Xiao-li |
author_facet | Tan, Si-hua Zhou, Xiao-li |
author_sort | Tan, Si-hua |
collection | PubMed |
description | BACKGROUND AND AIMS: Non-alcoholic fatty liver disease (NAFLD) is a multisystem disease closely linked to cardiovascular disease (CVD). This study aims to investigate the connection between early-stage NAFLD and atherosclerosis, as well as the correlation between liver fibrosis and coronary heart disease while exploring underlying inflammatory mechanisms. METHODS: In this retrospective study, the authors analyzed data from 607 patients who underwent both coronary computed tomography angiography (CCTA) and abdominal ultrasonography (US). Logistic regression was utilized to examine the association between NAFLD and atherosclerosis, while mediation analysis was conducted to explore whether inflammatory markers mediate the link between liver fibrosis and coronary artery disease. RESULTS: Among the 607 patients included, 237 (39.0 %) were diagnosed with NAFLD through ultrasonography. After adjusting for traditional cardiovascular risk factors, ALT, and AST, NAFLD demonstrated a significant correlation with carotid intimal thickening (1.58, 95 % CI 1.04‒2.40; p = 0.034) and non-calcified plaque (1.56, 95 % CI 1.03‒2.37; p = 0.038). Additionally, fibrosis predictive markers, including FIB-4 > 1.3 (1.06, 95 % CI 2.30‒5.00; p = 0.035) and APRI (6.26, 95 % CI 1.03‒37.05; p = 0.046), independently correlated with coronary heart disease after adjusting for cardiovascular risk factors. Conversely, among systemic inflammatory markers, only the neutrophil-to-lymphocyte ratio (NLR) and systemic inflammatory response index (SIRI) are independently associated with coronary heart disease. ROC curve analysis indicated that combining predictive fibrosis markers or inflammatory markers with traditional cardiovascular risk factors enhanced the predictive accuracy for coronary heart disease. Mediation analysis revealed that NLR fully mediated the effect of liver fibrosis on coronary heart disease. CONCLUSION: NAFLD is associated with carotid intimal thickening and non-calcified plaque, suggesting an increased cardiovascular risk. Furthermore, liver fibrosis independently increases the risk of coronary heart disease in the early-stage NAFLD population, and inflammation may play a fully mediating role in the effect of liver fibrosis on coronary heart disease. Early intervention is crucial for NAFLD patients to mitigate future major adverse cardiovascular events. |
format | Online Article Text |
id | pubmed-10681951 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo |
record_format | MEDLINE/PubMed |
spelling | pubmed-106819512023-11-30 Early-stage non-alcoholic fatty liver disease in relation to atherosclerosis and inflammation Tan, Si-hua Zhou, Xiao-li Clinics (Sao Paulo) Original Articles BACKGROUND AND AIMS: Non-alcoholic fatty liver disease (NAFLD) is a multisystem disease closely linked to cardiovascular disease (CVD). This study aims to investigate the connection between early-stage NAFLD and atherosclerosis, as well as the correlation between liver fibrosis and coronary heart disease while exploring underlying inflammatory mechanisms. METHODS: In this retrospective study, the authors analyzed data from 607 patients who underwent both coronary computed tomography angiography (CCTA) and abdominal ultrasonography (US). Logistic regression was utilized to examine the association between NAFLD and atherosclerosis, while mediation analysis was conducted to explore whether inflammatory markers mediate the link between liver fibrosis and coronary artery disease. RESULTS: Among the 607 patients included, 237 (39.0 %) were diagnosed with NAFLD through ultrasonography. After adjusting for traditional cardiovascular risk factors, ALT, and AST, NAFLD demonstrated a significant correlation with carotid intimal thickening (1.58, 95 % CI 1.04‒2.40; p = 0.034) and non-calcified plaque (1.56, 95 % CI 1.03‒2.37; p = 0.038). Additionally, fibrosis predictive markers, including FIB-4 > 1.3 (1.06, 95 % CI 2.30‒5.00; p = 0.035) and APRI (6.26, 95 % CI 1.03‒37.05; p = 0.046), independently correlated with coronary heart disease after adjusting for cardiovascular risk factors. Conversely, among systemic inflammatory markers, only the neutrophil-to-lymphocyte ratio (NLR) and systemic inflammatory response index (SIRI) are independently associated with coronary heart disease. ROC curve analysis indicated that combining predictive fibrosis markers or inflammatory markers with traditional cardiovascular risk factors enhanced the predictive accuracy for coronary heart disease. Mediation analysis revealed that NLR fully mediated the effect of liver fibrosis on coronary heart disease. CONCLUSION: NAFLD is associated with carotid intimal thickening and non-calcified plaque, suggesting an increased cardiovascular risk. Furthermore, liver fibrosis independently increases the risk of coronary heart disease in the early-stage NAFLD population, and inflammation may play a fully mediating role in the effect of liver fibrosis on coronary heart disease. Early intervention is crucial for NAFLD patients to mitigate future major adverse cardiovascular events. Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo 2023-11-11 /pmc/articles/PMC10681951/ /pubmed/37952443 http://dx.doi.org/10.1016/j.clinsp.2023.100301 Text en © 2023 HCFMUSP. Published by Elsevier España, S.L.U. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Original Articles Tan, Si-hua Zhou, Xiao-li Early-stage non-alcoholic fatty liver disease in relation to atherosclerosis and inflammation |
title | Early-stage non-alcoholic fatty liver disease in relation to atherosclerosis and inflammation |
title_full | Early-stage non-alcoholic fatty liver disease in relation to atherosclerosis and inflammation |
title_fullStr | Early-stage non-alcoholic fatty liver disease in relation to atherosclerosis and inflammation |
title_full_unstemmed | Early-stage non-alcoholic fatty liver disease in relation to atherosclerosis and inflammation |
title_short | Early-stage non-alcoholic fatty liver disease in relation to atherosclerosis and inflammation |
title_sort | early-stage non-alcoholic fatty liver disease in relation to atherosclerosis and inflammation |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681951/ https://www.ncbi.nlm.nih.gov/pubmed/37952443 http://dx.doi.org/10.1016/j.clinsp.2023.100301 |
work_keys_str_mv | AT tansihua earlystagenonalcoholicfattyliverdiseaseinrelationtoatherosclerosisandinflammation AT zhouxiaoli earlystagenonalcoholicfattyliverdiseaseinrelationtoatherosclerosisandinflammation |